Palestine News

Bimekizumab well tolerated, efficacious over three years in axial spondyloarthritis

Written by

wpadmin

in

For patients with axial spondyloarthritis (axSpA), bimekizumab, a dual interleukin (IL)-17A and IL-17F inhibitor, is well tolerated over three years, according to a study

Continue Reading


News Source: medicalxpress.com

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

More posts